uveitis
Conditions
Interventions
Intravitreal FAI insert group:Intravitreal FAI insert
External control group(Traditional clinical treatment):No
Sponsors
Boao Super Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects volunteered to participate in the study; 2.Subject was diagnosed as chronic NIU-PS with one or both eyes
Exclusion criteria
Exclusion criteria: 1.Allergy to fluocinolone acetonide or any component of the FAI insert. 2.Eye or periocular infectious disease. 3.Pregnant or nursing females; All subjects of childbearing age (male and female) who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity (BCVA);Recurrence rate of uveitis; | — |
Secondary
| Measure | Time frame |
|---|---|
| best corrected visual acuity (BCVA);Systemic hormone treatment volume;In FAI implant group, macular edema measured by OCT compared with baseline (months 6, 12, and 36);Proportion of recurrence of uveitis;Time of first recurrence of uveitis compared with external control group;Mean change from baseline in BCVA compared to the external control group (months 6, 12, and 36);Changes in the amount of systemic sex hormone therapy in patients compared with the external control group (months 6, 12, and 36);Optical coherence tomography(OCT) measured macular edema compared to the external control group (months 6, 12, and 36); | — |
Countries
China
Contacts
Public ContactQu Jia/Wei Chen
Outcome results
None listed